xml version="1.0" encoding="utf-8"?                

   0000310158 false        0000310158   2021-01-26 2021-01-26     0000310158  us-gaap:CommonStockMember    2021-01-26 2021-01-26     0000310158  mrk:Sec1.125NotesDue2021Member    2021-01-26 2021-01-26     0000310158  mrk:Sec0.500NotesDue2024Member    2021-01-26 2021-01-26     0000310158  mrk:Sec1.875NotesDue2026Member    2021-01-26 2021-01-26     0000310158  mrk:Sec2.500NotesDue2034Member    2021-01-26 2021-01-26     0000310158  mrk:Sec1.375NotesDue2036Member    2021-01-26 2021-01-26    iso4217:USD   xbrli:shares     iso4217:USD   xbrli:shares       

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 

Date of report (Date of earliest event reported): February 1, 2021 (January 26, 2021) 

Merck & Co., Inc. 

(Exact name of registrant as specified in its charter) 

  [DATA_TABLE_REMOVED] 

  [DATA_TABLE_REMOVED] 

(Registrant’s telephone number, including area code) (908) 740-4000 

 Not Applicable   

  (Former name, former address, and former fiscal year if changed since last report.)   

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company ¨ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ 

Securities registered pursuant to Section 12(b) of the Act: 

  [DATA_TABLE_REMOVED] 

 Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 

(d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the “Company”) on February 1, 2021, attached as Exhibit 99.1, announcing the election of Stephen L. Mayo to the Company’s Board of Directors (the “Board”), effective March 15, 2021. The Board appointed Dr. Mayo as a member of both the Research Committee and the Audit Committee of the Board. 

For his service on the Board, Dr. Mayo will receive compensation as a non-employee director in accordance with the Company’s non-employee director compensation practices described under the “Director Compensation” section of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 6, 2020. 

Dr. Mayo has no arrangements or understandings with any other person pursuant to which he was elected to the Board, nor does he have a relationship or related transaction with the Company that would require disclosure pursuant to Item 404(a) of Regulation S-K of the Securities and Exchange Commission in connection with his appointment as a director of the Company. 

 Item 9.01.Financial Statements and Exhibits.  

(d) Exhibits 

 99.1Press Release issued February 1, 2021  

 104Cover Page Interactive Data File (embedded within the Inline XBRL document)  

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

  [DATA_TABLE_REMOVED]